- Home
- ENGN vs LRMR Comparison
ENGN vs LRMR Comparison
Compare ENGN & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ENGN | LRMR |
|---|---|---|
| Founded | 1999 | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 379.3M | 332.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ENGN | LRMR |
|---|---|---|
| Price | $8.57 | $3.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $22.71 | $16.71 |
| AVG Volume (30 Days) | 314.7K | ★ 1.5M |
| Earning Date | 12-19-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.65 | $1.61 |
| 52 Week High | $11.14 | $5.37 |
Technical Indicators
Market Signals| Indicator | ENGN | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 56.36 | 48.57 |
| Support Level | $7.57 | $3.34 |
| Resistance Level | $8.47 | $4.15 |
| Average True Range (ATR) | 0.64 | 0.29 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 63.69 | 51.46 |
Price Performance
Historical ComparisonAbout ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.